HS Research Update (2026-06-01): What's New on PubMed? Canonical URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-06-01/ Markdown URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-06-01.md Plain text URL: https://www.acneinversa.life/en/blog/hs-research-update-2026-06-01.txt Language: en Category: Research Published: 2026-06-01 Last updated: 2026-06-01 Last editorially reviewed: 2026-06-01 Next scheduled review: 2027-06-01 Author: Dr. rer. nat. Dennis Alexander Kwiatkowski (Biochemist, Scientific Writer and Pharma Expert) Scientific editor: Dr. rer. nat. Dennis Alexander Kwiatkowski Reviewer qualifications: Biochemist, Scientific Writer and Pharma Expert Review scope: Scientific literature, clinical guidelines, sources, and editorial clarity Clinical reviewer: No independent clinical review Tags: Acne Inversa, Hidradenitis Suppurativa, HS, Research, hidradenitis suppurativa, acne inversa, research update, biologics, comorbidities, jak inhibitor, pain, quality of life, surgery, wound care A patient-friendly overview of new PubMed publications on Acne inversa (Hidradenitis suppurativa) (HS) — with sources, clear limitations, and no treatment recommendations. Medical disclaimer: This website is for general educational information only and does not replace medical advice, diagnosis, or treatment. Please speak with qualified medical professionals about symptoms or treatment decisions. Article Publication Overview This update includes 11 PubMed publications with an abstract from the monitoring period 2026-05-24 to 2026-06-01. The most common focus areas are biologics, wound care, pain, surgery, quality of life. - Comparison to the previous update: not automatically assessed. - No high-ranking guidelines/NEJM/Lancet hits with abstracts appeared in this window. - This selection is a research overview, not a guideline and not medical advice. Top Highlights The most important signal in this round is not "one new measure," but rather what researchers are currently focusing on more strongly: inflammatory pathways (including IL‑17), wound healing and tissue repair, the impact of HS on daily life, and the role of comorbidities. - Immunometabolism & chronic inflammation (review article): Links metabolism, inflammation, and skin diseases, and discusses why GLP‑1 receptor agonists are also being discussed in inflammatory contexts. Not an HS treatment study. (PMID 42198298 (https://pubmed.ncbi.nlm.nih.gov/42198298/)) - IL‑17 in HS (review of trials + real-world data): Summarizes what has been studied so far — and where evidence is still thin — rather than recommending "do this/don't do that." (PMID 42195203 (https://pubmed.ncbi.nlm.nih.gov/42195203/)) - Quality of life & major life decisions (cross-sectional study): Examines how HS can affect relationships, work, and long-term decisions — helpful context for goal-setting conversations at medical appointments. (PMID 42204891 (https://pubmed.ncbi.nlm.nih.gov/42204891/)) - Immune microenvironment of the skin (mechanistic review): Explains background on targeted therapies and why results can vary between individuals/conditions. (PMID 42200823 (https://pubmed.ncbi.nlm.nih.gov/42200823/)) - GLP‑1 biology & skin repair (review): Discusses tissue repair, inflammation, and skin biology — largely mechanistic, not a set of instructions. (PMID 42210887 (https://pubmed.ncbi.nlm.nih.gov/42210887/)) Featured Publication The featured paper is "GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives" from Pharmaceutics. (PMID 42198298 (https://pubmed.ncbi.nlm.nih.gov/42198298/)) What the abstract is about (explained simply): The authors classify inflammatory skin diseases (including HS) as conditions involving immune dysregulation that can also have systemic aspects. They summarize possible connections between metabolism, inflammation, and tissue repair — and why medications from metabolic medicine (such as GLP‑1 receptor agonists) are being discussed in broader inflammatory contexts. Why this is relevant — and the key limitations: The paper primarily provides a "conceptual framework" and possible mechanisms, but no evidence that a specific medication improves HS. Review articles are useful but do not replace controlled trials in HS populations. What This Could Mean for You (patient-friendly, without recommendations) If you live with HS, research updates can help you make sense of terms and trends — for example, which measures (pain, quality of life) are used in studies, or which comorbidities are being considered more often. Important: Even if individual studies sound exciting, they usually don't yet say anything about what is right for you personally. Use new findings as a conversation starter (e.g., "What goals are realistic for me?" or "Which comorbidities should I keep an eye on?") — not as instructions for action. What We Don't Know / Limitations - This update considers only PubMed entries with an abstract (without an abstract, a reliable summary is hardly possible). - Studies vary greatly (design, population, measurement methods). - This update provides no treatment recommendations and does not assess individual risks. Important: Decisions Belong in the Doctor's Office This article is an editorial overview and has not been medically reviewed. If anything in this overview makes you feel unsure or interested, use it as a conversation starter for your next appointment. Medications, surgeries, and diagnostics should always be discussed together with qualified medical professionals. FAQ Why are only publications with an abstract included? Without an abstract, it's difficult to responsibly summarize content in a short, patient-friendly format. Does a hit in this list mean I should change something about my treatment? No. This post is not medical advice. It simply shows what has recently been published. How do I make good use of this? Bring one or two points as conversation starters to your medical appointment (goals, symptom tracking, comorbidities, realistic expectations). Sources & Original Studies For each point, you'll find the original source below (PubMed link, and DOI/PMCID if available). References 1. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity. - Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2026 — PMID 42210887 · DOI 10.1097/DSS.0000000000005187 - https://pubmed.ncbi.nlm.nih.gov/42210887/ 2. Hidradenitis suppurativa-associated squamous cell carcinoma: a systematic review of clinical, molecular, and risk factor insights. - Italian journal of dermatology and venereology, 2026 — PMID 42206557 · DOI 10.23736/S2784-8671.26.08519-1 - https://pubmed.ncbi.nlm.nih.gov/42206557/ 3. Hidradenitis Suppurativa Changes Major Life Decisions of Affected Patients: A Cross-sectional Study. - Acta dermato-venereologica, 2026 — PMID 42204891 · DOI 10.2340/actadv.v106.adv-2026-0427 · PMCID PMC13216440 - https://pubmed.ncbi.nlm.nih.gov/42204891/ 4. Shorter Wound-healing Times Associated With Select Perioperative Medical Therapies in Hidradenitis Suppurativa Surgery, and a Limited Clinical Role of Intraoperative Cultures: A 194-Case Retrospective Review. - Annals of plastic surgery, 2026 — PMID 42201339 · DOI 10.1097/SAP.0000000000004777 - https://pubmed.ncbi.nlm.nih.gov/42201339/ 5. Prevalence and Characteristics of North American Indigenous Inflammatory Skin Disease: A Systematic Scoping Review. - International journal of dermatology, 2026 — PMID 42179093 · DOI 10.1111/ijd.70470 - https://pubmed.ncbi.nlm.nih.gov/42179093/ 6. Cutaneous tuberculosis with features suggestive of scrofuloderma masquerading as hidradenitis suppurativa: a case report. - Therapeutic advances in infectious disease, 2026 — PMID 42182972 · DOI 10.1177/20499361261449091 · PMCID PMC13195225 - https://pubmed.ncbi.nlm.nih.gov/42182972/ 7. A phenotype-to-mechanism framework links phenome-wide comorbidity architecture to molecular mechanisms and therapeutic discovery in complex diseases. - medRxiv : the preprint server for health sciences, 2026 — PMID 42180332 · DOI 10.64898/2026.05.13.26353128 · PMCID PMC13193042 - https://pubmed.ncbi.nlm.nih.gov/42180332/ 8. GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives. - Pharmaceutics, 2026 — PMID 42198298 · DOI 10.3390/pharmaceutics18050605 · PMCID PMC13210952 - https://pubmed.ncbi.nlm.nih.gov/42198298/ 9. A Neuroendocrine-Immune Model of Hidradenitis Suppurativa: Mechanistic Insights into Pain, Pruritus, and Hormonal Triggers. - Journal of clinical medicine, 2026 — PMID 42194774 · DOI 10.3390/jcm15103820 · PMCID PMC13207860 - https://pubmed.ncbi.nlm.nih.gov/42194774/ 10. Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data. - Medicina (Kaunas, Lithuania), 2026 — PMID 42195203 · DOI 10.3390/medicina62050952 · PMCID PMC13208325 - https://pubmed.ncbi.nlm.nih.gov/42195203/ 11. The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy. - Dermatopathology (Basel, Switzerland), 2026 — PMID 42200823 · DOI 10.3390/dermatopathology13020022 · PMCID PMC13214635 - https://pubmed.ncbi.nlm.nih.gov/42200823/